

19. Sharpe C, Davis J, Mason KD, et al. More Than a BTK Inhibitor; Ibrutinib Profoundly Impacts the Function of Cell Mediated Immunity. *Blood*. 2018;132(Supplement 1):4417-4417.
20. Thangavadivel S, Mao C, Long M, et al. T Cell Dysfunction and Exhaustion in Patients with CLL: The Impact of Long Term Ibrutinib Treatment. *Blood*. 2023;142(Supplement 1):4631-4631.
21. de Weerd I, Hofland T, de Boer R, et al. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. *Blood Adv*. 2019;3(17):2642-2652.
22. Kater AP, Eichhorst B, Owen C, et al. Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia. *Blood*. 2022;140(Supplement 1):7010-7012.
23. Langerbeins P, Zhang C, Robrecht S, et al. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. *Blood*. 2022;139(2):177-187.
24. Rogers KA, Zhao Q, Bhat SA, et al. Extended Follow up of a Phase 2 Study of Early Intervention with Lenalidomide in Patients with High-Risk Chronic Lymphocytic Leukemia. *Blood*. 2023;142(Supplement 1):3272-3272.
25. Al-Sawaf O, Zhang C, Jin HY, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. *Nature Communications*. 2023;14(1):2147.
26. Niemann CU, Munir T, Moreno C, et al. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. *The Lancet Oncology*. 2023;24(12):1423-1433.
27. Thompson PA, Bazinet A, Wierda WG, et al. Sustained remissions in CLL after frontline FCR treatment with very long-term follow-up. *Blood*. 2023;blood.2023020158.
28. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. *J Clin Oncol*. 2018;36(19):1973-1980.
29. Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. *The Lancet Oncology*. 2022;23(8):1031-1043.
30. Woyach JA, Perez Burbano G, Ruppert AS, et al. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. *Blood*. 2024;143(16):1616-1627.
31. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN. *Blood*. 2023;142(Supplement 1):636-636.
32. Chiang CL, Hu EY, Chang L, et al. Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity. *Cell Reports*. 2022;40(3):111115.
33. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. *Blood*. 2011;117(12):3391-3401.
34. Parry EM, ten Hacken E, Wu CJ. Richter syndrome: Novel insights into the biology of transformation. *Blood*. 2023;blood.2022016502.
35. Parry EM, Leshchiner I, Guièze R, et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. *Nature Medicine*. 2023;1:12.
36. Nadeu F, Royo R, Massoni-Badosa R, et al. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia. *Nature Medicine*. 2022;28(8):1662-1671.
37. Davids MS, Rogers KA, Tyekuceva S, et al. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. *Blood*. 2022;139(5):686-689.
38. Frustaci AM, Montillo M, Rossi D, et al. Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome. *Journal of Clinical Oncology*. 2023;41(16_suppl):7502-7502.
39. Kittai AS, Bond DA, Huang Y, et al. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study. *Blood*. 2023;142(Supplement 1):108-108.

VZDĚLÁVEJTE SE ON-LINE a získejte kredity

- získejte 2–12 kreditů za kurz
- vyberte si z různých medicínských specializací
- vzdělávejte se dle svých časových možností

SOLEN
MEDICAL EDUCATION



www.solen.cz



**On-line
vzdělávání**